Insider Selling: GlycoMimetics, Inc. (GLYC) SVP Sells 2,000 Shares of Stock
GlycoMimetics, Inc. (NASDAQ:GLYC) SVP Helen M. Thackray sold 2,000 shares of the company’s stock in a transaction dated Friday, December 8th. The shares were sold at an average price of $15.01, for a total transaction of $30,020.00. Following the completion of the sale, the senior vice president now owns 148,615 shares in the company, valued at approximately $2,230,711.15. The sale was disclosed in a filing with the SEC, which is accessible through this link.
GlycoMimetics, Inc. (NASDAQ GLYC) traded up $2.13 on Tuesday, reaching $16.45. 6,594,456 shares of the company traded hands, compared to its average volume of 945,008. GlycoMimetics, Inc. has a 52-week low of $3.82 and a 52-week high of $18.25.
GlycoMimetics (NASDAQ:GLYC) last released its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.04. analysts expect that GlycoMimetics, Inc. will post -1.12 EPS for the current year.
Several research firms recently weighed in on GLYC. SunTrust Banks increased their price objective on shares of GlycoMimetics to $32.00 and gave the stock a “buy” rating in a research note on Tuesday. Cowen reiterated a “buy” rating on shares of GlycoMimetics in a research note on Wednesday, December 6th. BidaskClub upgraded shares of GlycoMimetics from a “sell” rating to a “hold” rating in a research note on Wednesday, December 6th. Roth Capital began coverage on shares of GlycoMimetics in a research note on Monday, October 23rd. They set a “buy” rating and a $25.00 price objective on the stock. Finally, Zacks Investment Research upgraded shares of GlycoMimetics from a “hold” rating to a “buy” rating and set a $13.00 price objective on the stock in a research note on Monday, November 13th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. GlycoMimetics currently has a consensus rating of “Buy” and a consensus target price of $19.17.
COPYRIGHT VIOLATION WARNING: This article was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/12/12/insider-selling-glycomimetics-inc-glyc-svp-sells-2000-shares-of-stock.html.
GlycoMimetics Company Profile
GlycoMimetics, Inc is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease.
Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.